HSBC lowered the firm’s price target on Zoetis (ZTS) to $140 from $180 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis initiated with an Equal Weight at Barclays
- Zoetis announces Health Canada approval for Portela
- Zoetis Positioned for Long-Term Growth with Strategic Market Expansion and Innovative Product Launches
- Zoetis: Strong Innovation Pipeline and Attractive Valuation Justify Buy Rating Despite Near-Term Challenges
- Zoetis Hosts Innovation Webcast on Animal Health